| Literature DB >> 33063677 |
Ji Yeon Sung1, Jong Do Seo1, Dae-Hyun Ko2, Min-Jeong Park3, Sang Mee Hwang4, Sohee Oh5, Sail Chun2, Moon-Woo Seong1, Junghan Song1,4, Sang Hoon Song1, Sung Sup Park1.
Abstract
BACKGROUND: Reference intervals defined for adults or children of other ethnicities cannot be applied in the evaluation of Korean pediatric patients. Pediatric reference intervals are difficult to establish because children are in their growing stage and their physiology changes continuously. We aimed to establish reference intervals for routine laboratory tests for Korean pediatric patients through retrospective multicenter data analysis.Entities:
Keywords: Age-partitioned groups; Indirect sampling; Korean pediatrics; Multicenter; Reference intervals; Sex-partitioned groups
Mesh:
Year: 2021 PMID: 33063677 PMCID: PMC7591287 DOI: 10.3343/alm.2021.41.2.155
Source DB: PubMed Journal: Ann Lab Med ISSN: 2234-3806 Impact factor: 3.464
Age- and sex-specific pediatric reference intervals for hematology testing using the Sysmex XE-2100 system
| Analyte (unit) | Total N | Age | Sex | N | Lower limit (90% CI) | Upper limit (90% CI) |
|---|---|---|---|---|---|---|
| WBC (× 109/L) | 385 | 0–3 mo | M | 17 | 6.48 (4.74–8.10) | 16.30 (14.52–17.68) |
| F | 17 | 5.78 (4.12–7.66) | 15.80 (14.05–17.00) | |||
| 4–11 mo | Both | 67 | 4.64 (3.78–5.42) | 13.85 (12.98–14.77) | ||
| 1–6 yr | Both | 138 | 4.85 (4,62–5,60) | 11.50 (11.09–11.90) | ||
| 7–18 yr | Both | 146 | 4,32 (2,72–4,62) | 10.22 (9.57–10.20) | ||
| ANC (× 109/L) | 383 | 0–11 mo | Both | 97 | 0.65 | 3.35 |
| 1–18 yr | Both | 286 | 1.40 (1.22–1.51) | 5.76 (5.42–5.96) | ||
| Segmented neutrophils (%) | 393 | 0–11 mo | Both | 101 | 3.3 (1.1–5.5) | 33.1 (30.1–35.6) |
| 1–6 yr | Both | 147 | 16.9 (12.8–19.0) | 62.2 (56.3–65.6) | ||
| 7–12 yr | Both | 46 | 28.4 (25.1–32.2) | 64.5 (60.5–68.3) | ||
| 13–18 yr | Both | 99 | 38.3 (36.4–40.3) | 67.7 (65.6–69.8) | ||
| Lymphocytes (%) | 391 | 0–11 mo | Both | 100 | 54.5 (52.0–57.6) | 87.6 (85.2–89.8) |
| 1–6 yr | Both | 147 | 26.9 (24.9–35.1) | 73.8 (72.6–77.5) | ||
| 7–12 yr | Both | 45 | 29.4 (26.2–32.8) | 59.3 (56.3–62.0) | ||
| 13–18 yr | Both | 99 | 21.5 (19.3–23.6) | 51.5 (49.5–53.6) | ||
| Monocytes (%) | 387 | All | Both | 387 | 3.5 (3.0–3.7) | 10.4 (10.0–10.7) |
| Eosinophils (%) | 375 | All | M | 181 | 0.3 (0.1–0.7) | 6.9 (6.4–7.3) |
| F | 194 | 0.4 (0.1–0.7) | 5.7 (4.9–5.9) | |||
| Basophils (%) | 380 | All | Both | 380 | 0.1 (0.1–0.1) | 0.8 (0.8–0.9) |
| RBC (× 106/µL) | 390 | 0–3 mo | Both | 32 | 3.22 (3.07–3.41) | 4.65 (4.44–4.82) |
| 4 mo–18 yr | M | 174 | 4.16 (4.09–4.29) | 5.49 (5.30–5.62) | ||
| F | 184 | 4.03 (3.86–4.10) | 5.16 (5.03–5.29) | |||
| MCV (fL) | 395 | 0–3 mo | Both | 35 | 73.9 (71.2–76.6) | 98.3 (95.2–100.9) |
| 4–11 mo | M | 34 | 68.6 (66.9–70.6) | 82.8 (81.0–84.5) | ||
| F | 35 | 70.8 (69.1–72.5) | 84.6 (82.8–86.2) | |||
| 1–6 yr | M | 73 | 72.3 (71.5–73.2) | 83.4 (82.5–84.3) | ||
| F | 72 | 73.9 (72.8–75.0) | 86.1 (85.2–87.0) | |||
| 7–12 yr | M | 22 | 74.7 (73.1–76.6) | 87.8 (85.7–89.8) | ||
| F | 26 | 78.3 (77.0–79.9) | 89.0 (87.6–90.3) | |||
| 13–15 yr | M | 27 | 76.4 (74.3–78.7) | 93.3 (91.1–95.3) | ||
| F | 35 | 80.5 (79.0–82.1) | 94.3 (92.6–96.0) | |||
| 16–18 yr | M | 18 | 80.3 (78.3–82.6) | 95.2 (92.4–97.8) | ||
| F | 18 | 83.4 (81.6–85.6) | 95.9 (93.9–97.5) | |||
| MCH (pg) | 390 | 0–3 mo | Both | 35 | 25.3 (24.4–26.4) | 33.7 (32.7–34.6) |
| 4–11 mo | M | 32 | 23.5 (22.8–24.2) | 28.6 (28.0–29.2) | ||
| F | 31 | 24.9 (24.5–25.4) | 28.2 (27.9–28.5) | |||
| 1–6 yr | Both | 146 | 24.6 (24.3–25.2) | 29.1 (28.8–29.3) | ||
| 7–12 yr | Both | 48 | 26.4 (26.0–26.7) | 30.4 (29.9–30.8) | ||
| 13–15 yr | Both | 62 | 26.4 (25.8–26.9) | 32.2 (31.7–32.7) | ||
| 16–18 yr | Both | 36 | 28.0 (27.5–28.6) | 32.3 (31.8–32.8) | ||
| MCHC (g/L) | 386 | 0–12 yr | Both | 298 | 327 (325–329) | 359 (357–364) |
| 13–18 yr | M | 44 | 325 (322–328) | 357 (354–360) | ||
| F | 44 | 323 (321–326) | 343 (341–345) | |||
| Hb (g/L) | 393 | 0–3 mo | Both | 33 | 97 (92–101) | 134 (128–140) |
| 4 mo–6 yr | Both | 214 | 108 (107–111) | 140 (138–143) | ||
| 7–12 yr | M | 23 | 117† (112–123) | 154† (148–159) | ||
| F | 25 | 115 (110–120) | 148 (143–152) | |||
| 13–15 yr | M | 27 | 124 (119–129) | 164 (158–169) | ||
| F | 34 | 118 (114–122) | 150 (146–152) | |||
| 16–18 yr | M | 18 | 138† (132–143) | 170† (164–176) | ||
| F | 19 | 119† (114–123) | 146† (141–151) | |||
| Hct (proportion of 1.0) | 380 | 0–3 mo | Both | 27 | 0.31 (0.30–0.31) | 0.36 (0.36–0.37) |
| 4 mo–6 yr | Both | 211 | 0.33 (0.32–0.33) | 0.40 (0.39–0.41) | ||
| 7–12 yr | Both | 48 | 0.34 (0.34–0.35) | 0.43 (0.42–0.44) | ||
| 13–15 yr | M | 27 | 0.36 (0.34–0.37) | 0.48 (0.46–0.50) | ||
| F | 34 | 0.36 (0.35–0.37) | 0.44 (0.43–0.45) | |||
| 16–18 yr | M | 18 | 0.40 (0.39–0.42) | 0.50 (0.49–0.52) | ||
| F | 15 | 0.36† (0.35–0.37) | 0.42† (0.41–0.43) | |||
| RDW (%) | 390 | 0–3 mo | Both | 35 | 11.7 (11.2–12.2) | 16.3 (15.7–16.8) |
| 4 mo–6 yr | M | 105 | 12.0 (11.8–12.1) | 14.4 (14.2–14.6) | ||
| F | 106 | 11.7 (11.5–11.9) | 14.1 (13.9–14.3) | |||
| 7–18 yr | Both | 144 | 11.7 (11.3–11.9) | 13.8 (13.6–13.8) | ||
| ESR (mm/hr) | 225 | All | Both | 225 | 2 (2–2) | 9 (8–9) |
| Platelets (× 109/L) | 390 | 0–3 mo | Both | 35 | 188 (143–243) | 610 (558–663) |
| 4–11 mo | Both | 65 | 199 (174–224) | 495 (467–520) | ||
| 1–12 yr | Both | 192 | 178 (171–192) | 414 (389–434) | ||
| 13–18 yr | Both | 98 | 165 (151–179) | 365 (351–379) | ||
| PCT (%) | 390 | 0–11 mo | Both | 102 | 0.17 (0.15–0.19) | 0.52 (0.49–0.54) |
| 1–18 yr | Both | 288 | 0.17 (0.15–0.18) | 0.38 (0.36–0.39) | ||
| MPV (fL) | 373 | 0–6 yr | Both | 236 | 7.6 (7.5–8.0) | 10.9 (10.5–11.1) |
| 7–18 yr | Both | 137 | 8.8 (8.6–9.1) | 11.4 (11.1–11.8) | ||
| PDW (%) | 358 | All | Both | 358 | 8.4 (8.1–8.6) | 13.3 (12.9–13.7) |
*Although the sample size was <120, the values presented were established using a nonparametric method because the 90% CI of the reference lower limit calculated using the robust method contained a negative value and the data did not pass a normality test; †The 90% CI was not determined using the robust method; however, the data passed a normality test and a parametric method based on the normal distribution was applied.
Abbreviations: CI, confidence interval; N/A, not applicable; yr, year; mo, month; M, male; F, female; ANC, absolute neutrophil count; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW, red cell distribution width; PCT, plateletcrit; MPV, mean platelet volume; PDW, platelet distribution width; WBC, white blood cells; RBC, red blood cells; MCV, mean corpuscular volume; ESR, erythrocyte sedimentation rate; Hct, hematocrit.
Age-specific pediatric reference intervals for coagulation testing using the ACL TOP system
| Analyte (unit) | Total N | Age | Sex | N | Lower limit (90% CI) | Upper limit (90% CI) |
|---|---|---|---|---|---|---|
| PT INR | 389 | 0–11 mo | Both | 102 | 0.87 (0.85–0.89) | 1.14 (1.12–1.16) |
| 1–18 yr | Both | 287 | 0.93 (0.91–0.94) | 1.17 (1.15–1.19) | ||
| PT (%) | 392 | 0–11 mo | Both | 100 | 82 (79–84) | 117 (114–120) |
| 1–18 yr | Both | 292 | 78 (73–81) | 111 (109–114) | ||
| PT (s) | 387 | 0–11 mo | Both | 100 | 9.6 (9.4–9.8) | 12.3 (12.1–12.5) |
| 1–18 yr | Both | 287 | 10.1 (10.0–10.3) | 12.8 (12.6–13.1) | ||
| aPTT (s) | 383 | All | Both | 383 | 28.3 (27.5–29.0) | 41.3 (40.8–41.7) |
| Fibrinogen (g/dL) | 67 | 0–12 yr | Both | 56 | 1.46 (1.31–1.63) | 3.21 (3.04–3.35) |
| 13–18 yr | Both | 11 | 1.96 | 3.79 |
*The 90% CI was not determined using a non-parametric method or robust method; however, the data passed a normality test and a parametric method based on the normal distribution was applied.
Abbreviations: PT, prothrombin time; INR, international normalized ratio; aPTT, activated partial thromboplastin time; yr, year; mo, month.
Age- and sex-specific pediatric reference intervals for chemistry testing using the TBA-c16000 system and multiple platforms, including Cobas 800, Hitachi 7600, and AU 5800, in the present study, and comparison with reference intervals from another single-center study in a Korean population and CALIPER study that were converted from conventional units to SI units
| Analyte (unit) | Total N | Age | Sex | This study | Severance Hospital [ | CALIPER [ | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Lower limit (90% CI) | Upper limit (90% CI) | Age | Lower limit | Upper limit | Age | Lower limit | Upper limit | ||||
| Calcium (mmol/L) | 387 | 0–11 mo | Both | 101 | 2.44 (2.41–2.47) | 2.85 (2.82–2.87) | 0–1 yr | 2.13 | 2.75 | |||
| 1–6 yr | Both | 143 | 2.28 (2.23–2.33) | 2.61 (2.60–2.70) | 1–19 yr | 2.30 | 2.63 | |||||
| 7–18 yr | Both | 143 | 2.23 (2.20–2.25) | 2.53 (2.48–2.53) | ||||||||
| Multicenter combined (T+C+H) | 780 | 0–11 mo | Both | 270 | 2.43 (2.40–2.48) | 2.81 (2.80–2.85) | ||||||
| 1–6 yr | Both | 280 | 2.28 (2.25–2.30) | 2.67 (2.63–2.70) | ||||||||
| 7–18 yr | Both | 230 | 2.20 (2.15–2.23) | 2.58 (2.55–2.63) | ||||||||
| Phosphorus (mmol/L) | 390 | 0–3 mo | Both | 32 | 1.74 (1.63–1.85) | 2.54 (2.45–2.61) | M: 2–16 yr | 1.23 | 1.91 | |||
| 4–11 mo | Both | 68 | 1.57 (1.51–1.63) | 2.29 (2.23–2.35) | F: 2–14 yr | 1.26 | 1.87 | |||||
| 1–6 yr | Both | 147 | 1.42 (1.26–1.45) | 2.07 (2.00–2.16) | ||||||||
| 7–12 yr | M | 23 | 1.26 (1.16–1.41) | 2.02 (1.92–2.15) | ||||||||
| F | 23 | 1.15 | 1.80 | |||||||||
| 13–18 yr | Both | 97 | 1.01 (0.96–1.06) | 1.73 (1.67–1.78) | ||||||||
| Glucose (mmol/L) | 377 | All | Both | 377 | 4.38 (4.11–4.44) | 6.44 (6.33–6.49) | M: 2–16 yr | 4.16 | 6.49 | |||
| Multicenter combined (T+C) | 655 | All | Both | 655 | 4.38 (4.16–4.50) | 6.42 (6.33–6.49) | F: 2–14 yr | 4.11 | 6.72 | |||
| BUN (mg/dL) | 396 | 0–11 mo | Both | 101 | 0.40 (0.11–0.70) | 5.17 (4.85–5.61) | 0–14 d | 1.00 | 8.21 | |||
| 1–18 yr | Both | 295 | 2.28 (2.14–2.50) | 6.07 (6.07–6.43) | 15 d–1 yr | 1.21 | 6.00 | |||||
| 1–10 yr | 3.21 | 7.89 | ||||||||||
| 10–19 yr | M: 2.61, F: 2.61 M: | 7.50, F: 6.78 | ||||||||||
| Uric acid (mmol/L) | 357 | 0–3 mo | Both | 33 | 0.08 (0.06–0.10) | 0.25 (0.23–0.27) | M: 2–10 yr | 0.15 | 0.35 | |||
| 4 mo–6 yr | Both | 204 | 0.12 (0.11–0.14) | 0.30 (0.29–0.34) | M: 11–16 yr | 0.18 | 0.45 | |||||
| 7–12 yr | M | 21 | 0.16 (0.14–0.19) | 0.37 (0.33–0.40) | F: 2–14 yr | 0.15 | 0.35 | |||||
| F | 25 | 0.12 (0.09–0.15) | 0.37 (0.33–0.40) | |||||||||
| 13–18 yr | M | 34 | 0.23 (0.21–0.27) | 0.46 (0.43–0.49) | ||||||||
| F | 40 | 0.16 (0.14–0.18) | 0.36 (0.34–0.39) | |||||||||
| Cholesterol (mmol/L) | 388 | All | Both | 388 | 2.95 (2.82–3.06) | 5.64 (5.46–5.83) | M: 2–16 yr | 3.16 | 5.41 | 0–14 d | M: 1.09, F: 1.19 M: | 2.82, F: 3.24 |
| Multicenter combined (T+H) | 489 | All | Both | 489 | 2.90 (2.82–3.03) | 5.72 (5.52–5.85) | F: 2–14 yr | 3.32 | 5.46 | 15 d–1 yr | 1.66 | 6.14 |
| 1–19 yr | 2.90 | 5.39 | ||||||||||
| Total Protein (g/L) | 389 | 0–3 mo | Both | 32 | 53.6 (51.1–56.4) | 75.0 (72.4–77.2) | M: 2–5 yr | 61 | 74 | 0–14 d | 53 | 83 |
| 4–11 mo | Both | 70 | 58.5 (57.0–59.7) | 74.7 (73.0–76.2) | M: 6–16 yr | 63 | 77 | 15 d–1 yr | 44 | 71 | ||
| 1–6 yr | Both | 147 | 64.0 (61.0–64.0) | 78.0 (76.0–79.0) | F: 2–14 yr | 63 | 77 | 1–6 yr | 61 | 75 | ||
| 7–12 yr | M | 20 | 68.5 | 76.2 | 6–9 yr | 64 | 77 | |||||
| F | 25 | 65.0 | 78.8 | 9–19 yr | 65 | 81 | ||||||
| 13–18 yr | Both | 95 | 68.7 (67.8–69.6) | 80.9 (80.1–81.8) | ||||||||
| Albumin | 394 | All | Both | 394 | 40 (39–41) | 50 (50–51) | M: 2–16 yr | 40 | 49 | 0–14 d | 33 | 45 |
| F: 2–14 yr | 40 | 49 | 15 d–1 yr | 28 | 47 | |||||||
| 1–8 yr | 38 | 47 | ||||||||||
| 8–15 yr | 41 | 48 | ||||||||||
| 15–19 yr | M: 41, F: 40 | M: 51, F: 49 | ||||||||||
| Total bilirubin (µmol/L) | 367 | All | Both | 367 | 3.4 (3.4–3.4) | 13.7 (13.7–13.7) | M: 2–8 yr | 3.4 | 13.7 | 0–14 d | 3.2 | 283.9 |
| M: 9–16 yr | 3.4 | 17.1 | 15 d –1 yr | 0.9 | 11.6 | |||||||
| F: 2– 9 yr | 3.4 | 13.7 | 1–9 yr | 0.9 | 6.8 | |||||||
| F: 10–14 yr | 3.4 | 17.1 | 9–12 yr | 0.9 | 9.4 | |||||||
| 12–15 yr | 1.7 | 12.0 | ||||||||||
| 15–19 yr | 1.7 | 14.4 | ||||||||||
| ALP (µkat/L) | 268 | 0–12 yr | Both | 212 | 2.01 (1.64–2.47) | 5.75 (5.46–6.20) | M: 2–5 yr | 1.77 | 4.35 | 0–14 d | 1.50 | 4.55 |
| 13–15 yr | M | 13 | 1.04 | 5.66 | M: 6–14 yr | 1.97 | 5.68 | 15 d–1 yr | 2.23 | 8.63 | ||
| F | 17 | 0.92 | 2.76 | M: 15–16 yr | 1.03 | 4.17 | 1–10 yr | 2.60 | 6.15 | |||
| 16–18 yr | M | 13 | 0.96 | 1.89 | F: 2–5 yr | 1.95 | 4.35 | 10–13 yr | 2.35 | 7.67 | ||
| F | 13 | 0.57 | 1.61 | F: 6–12 yr | 2.05 | 5.50 | 13–15 yr | M: 2.12, F: 1.03 | M: 8.62, F: 4.67 | |||
| F: 13–14 yr | 1.02 | 6.65 | 15–17 yr | M: 1.48, F: 0.90 | M: 6.08, F: 2.13 | |||||||
| 17–19 yr | M: 0.98, F: 0.80 | M: 2.73, F: 1.58 | ||||||||||
| AST (GOT) (µkat/L) | 376 | 0–11 mo | Both | 97 | 0.25 (0.19–0.33) | 1.15 (1.07–1.24) | M: 2–16 yr | 0.25 | 0.65 | 0–14 d | 0.53 | 2.70 |
| 1–6 yr | Both | 144 | 0.38 (0.35–0.40) | 0.80 (0.75–0.85) | F: 2–7 yr | 0.33 | 0.68 | 15 d–1 yr | 0.30 | 1.12 | ||
| 7–12 yr | M | 19 | 0.27 | 0.63 | F: 8–14 yr | 0.23 | 0.57 | 1–7 yr | 0.35 | 0.73 | ||
| F | 25 | 0.22 | 0.51 | 7–12 yr | 0.30 | 0.60 | ||||||
| 13–18 yr | Both | 91 | 0.17 (0.16–0.19) | 0.42 (0.39–0.43) | 12–19 yr | M: 0.23, F: 0.22 | M: 0.58, F: 0.43 | |||||
| ALT (GPT) (µkat/L) | 380 | 0–11 mo | Both | 98 | 0.23 | 1.01 | M: 2–16 yr | 0.13 | 0.65 | 0–1 yr | 0.08 | 0.55 |
| 1–18 yr | Both | 282 | 0.12 (0.12–0.13) | 0.45 (0.43–0.52) | F: 2–14 yr | 0.12 | 0.52 | 1–13 yr | 0.15 | 0.42 | ||
| 13–19 yr | M: 0.15, F: 0.13 | M: 0.40, F: 0.37 | ||||||||||
| Creatinine | 391 | 0–3 mo | Both | 33 | 13.4 (11.3–15.8) | 31.7 (29.7–34.2) | M: 2–5 yr | 19.4 | 49.5 | 0–14 d | 37.1 | 92.8 |
| 4–11 mo | Both | 69 | 18.5 (17.1–20.0) | 33.4 (32.3–34.8) | M: 6–9 yr | 28.3 | 61.9 | 15 d–1 yr | 28.3 | 46.9 | ||
| 1–6 yr | Both | 147 | 23.0 (18.6–23.9) | 46.5 (43.3–47.1) | M: 10–12 yr | 34.5 | 70.7 | 1–4 yr | 33.6 | 47.7 | ||
| 7–12 yr | Both | 48 | 30.2 (27.4–33.5) | 66.2 (62.0–70.0) | M: 13–16 yr | 39.8 | 86.6 | 4–7 yr | 38.9 | 56.6 | ||
| 13–15 yr | M | 27 | 38.7 (31.8–47.4) | 97.1 (89.4–104.3) | F: 2–5 yr | 18.6 | 46.9 | 7–12 yr | 46.0 | 61.0 | ||
| F | 30 | 44.4 (41.2–48.3) | 71.7 (68.1–75.7) | F: 6–8 yr | 28.3 | 56.6 | 12–15 yr | 50.4 | 70.7 | |||
| 16–18 yr | M | 18 | 61.7 | 102.8 | F: 9–14 yr | 32.7 | 63.6 | 15–17 yr | M: 58.3, F: 52.2 | M: 91.9, F: 76.0 | ||
| F | 19 | 48.9 | 77.8 | 17–19 yr | M: 61.0, F: 53.0 | M: 97.2, F: 77.8 | ||||||
| Na (mmol/L) | 392 | 0–6 yr | Both | 248 | 134 (133–134) | 141 (140–141) | ||||||
| 7–18 yr | Both | 144 | 136 (135–136) | 142 (142–143) | ||||||||
| Multicenter combined (T+C+A) | 909 | 0–3 mo | Both | 42 | 132 (131–133) | 142 (141–143) | ||||||
| 4 mo–6 yr | Both | 603 | 135 (135–136) | 143 (142–143) | ||||||||
| 7–18 yr | Both | 264 | 136 (135–136) | 144 (143–144) | ||||||||
| K (mmol/L) | 389 | 0–3 mo | Both | 33 | 4.5 (4.2–4.7) | 6.3 (6.1–6.5) | ||||||
| 4–11 mo | Both | 67 | 4.1 (4.0–4.2) | 5.3 (5.2–5.4) | ||||||||
| 1–18 yr | Both | 289 | 3.7 (3.6–3.7) | 4.8 (4.7–4.9) | ||||||||
| Multicenter combined (T+C+A) | 911 | 0–3 mo | M | 20 | 4.7 | 6.2 | ||||||
| F | 21 | 4.3 | 6.2 | |||||||||
| 4–11 mo | Both | 248 | 4.2 (4.0–4.3) | 5.4 (5.3–5.5) | ||||||||
| 1–18 yr | Both | 622 | 3.7 (3.7–3.8) | 5.0 (4.9–5.1) | ||||||||
| Cl (mmol/L) | 398 | All | Both | 398 | 100 (99–100) | 108 (108–109) | ||||||
| Multicenter combined (T+C+A) | 890 | All | Both | 890 | 101 (100–101) | 107 (107–108) | ||||||
| TCO2 (mmol/L) | 393 | 0–6 yr | Both | 248 | 17 (17–18) | 26 (26–28) | 0–14 d | 5 | 20 | |||
| 7–12 yr | Both | 47 | 21 | 29 | 15 d–1 yr | 10 | 24 | |||||
| 13–18 yr | Both | 98 | 21 (20–22) | 31 (30–32) | 1–5 yr | 14 | 24 | |||||
| 5–15 yr | 17 | 26 | ||||||||||
| 15–19 yr | M: 18, F: 17 | M: 28, F: 26 | ||||||||||
| CRP (mg/L) | 241 | All | Both | 241 | 0.10 (0.10–0.10) | 1.80 (1.70–2.30) | 0–14 d | 0.3 | 6.1 | |||
| 15 d–15 yr | 0.1 | 1.0 | ||||||||||
| 15–19 yr | 0.1 | 1.7 | ||||||||||
*The 90% CI was not determined using the robust method; however, the data passed a normality test and a parametric method based on the normal distribution was applied; †Although the sample size was <120, the values presented were established using a nonparametric method because the 90% CI calculated using the robust method contained a negative value; ‡Age-specific group for the CALIPER study described as “A-B” means equal to or older than A, and younger than B; §Albumin concentration was measured using a bromocresol green dye-binding assay (AlbBCG). |Creatinine was measured using the Jaffe reaction.
Abbreviations: CALIPER, Canadian laboratory initiative on pediatric reference interval database; T, TBA-c16000; C, Cobas 800; H, Hitachi 7600; d, day; mo, month; yr, year; A, AU 5800; BUN, blood urea nitrogen; ALP, alkaline phosphatase; AST, aspartate aminotransferase; GOT, glutamate oxaloacetate transaminase; ALT, alanine aminotransferase; GPT, glutamate pyruvate transaminase; TCO2, total CO2; CRP, C-reactive protein.
Fig. 1Scatter plots of hematology test results showing age-dependent changes. Results obtained at SNUH using the Sysmex XE-2100 platform after outlier exclusion are presented. (A–D) WBC count, percentage of segmented neutrophils, lymphocytes, and eosinophils. (E–K) RBC count, MCV, MCH, MCHC, hemoglobin concentration, hematocrit, and RDW. (L–N) platelet count, PCT, and MPV. Blue and red dots represent male and female children enrolled in the present study. The gray line represents the trend line; its equation and r value are given.
Abbreviations: SNUH, Seoul National University Hospital; WBC, white blood cell; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RBC, red blood cell; RDW, RBC distribution width; PCT, plateletcrit; MPV, mean platelet volume; Hct, hematocrit.
Fig. 3Scatter plots of clinical chemistry results showing age-dependent changes. Reference intervals established in a previous study based mainly on a Caucasian population [8] are indicated as horizontal dashed lines. All test results that passed method comparison, considered mergeable, and subsequently used in multicenter analysis are plotted. (A–H) Calcium, phosphorus, BUN, uric acid, total protein, ALP, AST, and ALT. (I–L), creatinine, sodium, potassium, and TCO2. Blue and red dots represent male and female children enrolled in the present study. Blue, red, and black dashed lines represent male, female, and common reference limits established in a previous study, respectively. The gray line represents the trend line; its equation and r value are given.
Abbreviations: BUN, blood urea nitrogen; ALP alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Fig. 2Scatter plots of coagulation test results showing age-dependent changes. Results obtained at SNUH using the ACL TOP analyzer (Instrumentation Laboratory, Bedford, MA, USA) after outlier exclusion are presented. (A–D) PT INR, PT percentage, PT, and fibrinogen. Blue and red dots represent male and female children enrolled in the present study. The gray line represents the trend line; its equation and r value are given.
Abbreviations: SNUH, Seoul National University Hospital; PT, prothrombin time; INR, international normalized ratio.